"Mutations in the TTN gene, which are commonly found in idiopathic dilated cardiomyopathy, also seem common in peripartum cardiomyopathyâ€”which may finally help explain why the latter condition occurs, new research suggests.
Optison Side Effects Center
Medical Editor: John P. Cunha, DO, FACOEP
Optison (perflutren protein-type A microspheres) Injectable Suspension consists of microspheres of human serum albumin with perflutren for contrast enhancement used during certain ultrasound imaging procedures. Common side effects include headache, nausea/vomiting, warm sensation or flushing, and dizziness.
The recommended dose of Optison is 0.5 mL injected into a peripheral vein. This may be repeated for further contrast enhancement as needed. Optison may interact with other drugs. Tell your doctor all medications and supplements you use. During pregnancy, Optison should be used only if prescribed. It is unknown if this drug passes into breast milk. Consult your doctor before breastfeeding.
Our Optison (perflutren protein-type A microspheres) Injectable Suspension Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
What is Prescribing information?
The FDA package insert formatted in easy-to-find categories for health professionals and clinicians.
Optison FDA Prescribing Information: Side Effects
Clinical Trials Experience
OPTISON was administered in clinical studies in 279 patients. Of these patients there were 192 (68.8%) men and 87 (31.2%) women. The racial demographics were 199 (71.3%) Caucasian, 52 (18.6%) Black, 24 (8.6%) Hispanic, and 4 (1.4%) other racial or ethnic groups.
In these patients, 47 (16.8%) reported at least one adverse event. Of these one event was serious and required treatment with antihistamines for hypersensitivity manifestations of dizziness, nausea, flushing and temperature elevation. Deaths were not reported during the clinical studies.
Of the reported adverse reactions following the use of OPTISON the most frequently reported were headache (5.4%), nausea and/or vomiting (4.3%), warm sensation or flushing (3.6%), and dizziness (2.5%). The most common adverse events observed in clinical studies of OPTISON are given in Table 4.
Table 4: SELECTED ADVERSE EVENTS REPORTED IN ≥ 0.5% OF
THE SUBJECTS WHO RECEIVED OPTISONT IN CONTROLLED CLINICAL STUDIES (1)(2)
|No. of Patients Exposed to OPTISONT||279|
|No. of Patients Reporting on Adverse Event||47||(16.8%)|
|Body as a Whole||38||(13.6%)|
|Nausea and/or Vomiting||12||(4.3%)|
|Skin & Appendages||11||(3.9%)|
|Injection Site Discomfort||3||(1.1%)|
| (1) Patients are counted separately within each body system.
(2) The body system is reported if the aggregate is ≥ 0.5%. Details are not shown if the subsystem is not ≥ 0.5%.
Adverse events reported in < 0.5% of subjects who received OPTISON included: arthralgia, back pain, body or muscle aches, induration, urticaria, dry mouth, eosinophilia, palpitations, paresthesia, photophobia, premature ventricular contraction, pruritus, rash, irritableness, hypersensitivity, tinnitus, tremor, visual blurring, wheezing, oxygen saturation decline due to coughing, discoloration at the Heplock site, and burning sensation in the eyes.
Overall the reported adverse events with OPTISON were similar in type and frequency to those reported in the 199 patients who received ALBUNEX®.
In the clinical dose ranging studies of 40 normal volunteers, doses higher than those recommended in the DOSAGE AND ADMINISTRATION section tended to be associated with an increased frequency of reported adverse events.
In a prospective, post-marketing safety surveillance study of OPTISON used in routine clinical practice, a total of 1039 subjects received OPTISON. Of these patients, 648 (62.4%) were male and 391 (37.6%) were female with average age of 59.9 years (min, max: 20, 97). The racial distributions were 864 (83.2%) White, 141 (13.6%) Black, 18 (1.7%) Asian, and 16 (1.5%) other racial or ethnic groups. Overall, 175 patients (16.8%) reported at least one adverse event. No serious adverse reactions, including deaths, were reported in this study, suggesting that these reactions are unlikely to occur at a rate of more than 0.3% when OPTISON is used according to recommendations.
The following adverse reactions have been identified during the postmarketing use of OPTISON. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Cardiac arrests and other serious but non-fatal adverse reactions were uncommonly reported. Most of these uncommon reactions included cardiopulmonary symptoms and signs such as cardiac arrest, hypotension, supraventricular and ventricular arrhythmias, respiratory distress or decreased oxygenation. Reports also identified neurologic reactions (loss of consciousness or convulsions) as well as anaphylactoid reactions (see WARNINGS).
Read the entire FDA prescribing information for Optison (Perflutren Protein-Type A Microspheres)
Additional Optison Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get the latest treatment options.